Wall Street brokerages forecast that Jounce Therapeutics Inc (NASDAQ:JNCE) will report earnings of ($0.36) per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Jounce Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.23) and the lowest estimate coming in at ($0.46). Jounce Therapeutics reported earnings of ($0.34) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 5.9%. The firm is scheduled to announce its next quarterly earnings report on Thursday, March 14th.
According to Zacks, analysts expect that Jounce Therapeutics will report full-year earnings of ($1.14) per share for the current financial year, with EPS estimates ranging from ($1.24) to ($1.01). For the next year, analysts anticipate that the company will report earnings of ($1.30) per share, with EPS estimates ranging from ($2.33) to ($0.25). Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow Jounce Therapeutics.
Jounce Therapeutics (NASDAQ:JNCE) last issued its quarterly earnings results on Tuesday, November 13th. The company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.11. The company had revenue of $14.53 million for the quarter, compared to analyst estimates of $12.80 million. Jounce Therapeutics had a negative return on equity of 29.58% and a negative net margin of 59.74%.
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. increased its position in Jounce Therapeutics by 5.7% during the third quarter. Vanguard Group Inc. now owns 776,016 shares of the company’s stock worth $5,045,000 after buying an additional 41,945 shares during the last quarter. Man Group plc acquired a new stake in shares of Jounce Therapeutics during the third quarter worth $1,299,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Jounce Therapeutics during the third quarter worth $231,000. Renaissance Technologies LLC acquired a new stake in shares of Jounce Therapeutics during the third quarter worth $1,086,000. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Jounce Therapeutics by 153.0% during the third quarter. JPMorgan Chase & Co. now owns 440,029 shares of the company’s stock worth $2,861,000 after purchasing an additional 266,126 shares during the period. 82.60% of the stock is currently owned by hedge funds and other institutional investors.
NASDAQ:JNCE opened at $4.59 on Friday. The stock has a market capitalization of $141.27 million, a P/E ratio of -8.05 and a beta of 5.00. Jounce Therapeutics has a 52-week low of $3.30 and a 52-week high of $29.25.
About Jounce Therapeutics
Jounce Therapeutics, Inc, a clinical stage immunotherapy company, develops therapies for the treatment of cancer. Its lead product candidate is JTX-2011, a clinical stage monoclonal antibody that binds to and activates the inducible T cell co-stimulator, a protein on the surface of certain T cells found in solid tumors, which is in Phase I/II clinical trial for the treatment of six tumor types, including head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, melanoma, gastric cancer, and other tumor types identified through its translational science platform.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.